X

Drug Profile

Hepatitis C immune globulin - Cangene

Latest Information Update: 28 Feb 2014

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cangene Corporation
Developer Emergent BioSolutions
Class Antivirals; Immunoglobulins
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Hepatitis C

Most Recent Events

21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
20 Jul 2001 Cangene has stopped its phase II trial but is considering alternative approaches for further evaluation of this product
20 Jul 2001 Suspended-II for Hepatitis C in Canada (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com